A 20-Year Experience With Percutaneous Resection of Upper Tract Transitional Carcinoma: Is There an Oncologic Benefit With Adjuvant Bacillus Calmette Guérin Therapy?

Ardeshir R. Rastinehad, Michael C. Ost, Brian A. VanderBrink, Kathryn L. Greenberg, Assaad El-Hakim, Robert Marcovich, Gopal H. Badlani, Arthur D. Smith

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objectives: To determine whether there is an oncologic benefit of adjuvant bacillus Calmette Guérin (BCG) after resection of upper tract transitional cell carcinoma (UTTCC). Methods: A total of 133 renal units (RU) treated by percutaneous resection for UTTCC between 1985 and 2005 were retrospectively analyzed. Forty-four RU were excluded because of carcinoma in situ, high grade/stage, metastatic disease present at initial presentation, and/or the patient could tolerate loss of RU. Eighty-nine RU treated primarily by percutaneous resection were then analyzed. Fifty RU received adjuvant BCG therapy 2 weeks after endoscopic management for a total of 6 courses. Recurrence was defined as a positive biopsy result after the third-look nephroscopy. Progression of disease was assessed at time of recurrence and defined as an increase in grade/stage of disease. Results: Mean age (± SD) of 89 RU was 70.9 ± 11.1 years. Overall follow-up was 61.1 + 54.8 months. Grade distribution was 56.2% (50 of 89) and 43.8% (39 of 89) for low- and high-grade disease, respectively. There was no statistical difference with regard to tumor grade or stage between treated and nontreated groups (P > .05). Recurrence, time to recurrence, and progression of disease among RU treated with BCG were subselected by grade and compared with the corresponding nontreated group. Statistical significance between any of the treated and nontreated groups was not demonstrated (P > .05). Conclusions: Our data demonstrate that there is no overall oncologic benefit in the administration of adjuvant BCG with regard to disease recurrence, interval to recurrence, and progression of disease in the treatment of UTTCC.

Original languageEnglish (US)
Pages (from-to)27-31
Number of pages5
JournalUrology
Volume73
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Bacillus
Carcinoma
Kidney
Recurrence
Transitional Cell Carcinoma
Disease Progression
Therapeutics
Carcinoma in Situ
Biopsy
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

A 20-Year Experience With Percutaneous Resection of Upper Tract Transitional Carcinoma : Is There an Oncologic Benefit With Adjuvant Bacillus Calmette Guérin Therapy? / Rastinehad, Ardeshir R.; Ost, Michael C.; VanderBrink, Brian A.; Greenberg, Kathryn L.; El-Hakim, Assaad; Marcovich, Robert; Badlani, Gopal H.; Smith, Arthur D.

In: Urology, Vol. 73, No. 1, 01.2009, p. 27-31.

Research output: Contribution to journalArticle

Rastinehad, Ardeshir R. ; Ost, Michael C. ; VanderBrink, Brian A. ; Greenberg, Kathryn L. ; El-Hakim, Assaad ; Marcovich, Robert ; Badlani, Gopal H. ; Smith, Arthur D. / A 20-Year Experience With Percutaneous Resection of Upper Tract Transitional Carcinoma : Is There an Oncologic Benefit With Adjuvant Bacillus Calmette Guérin Therapy?. In: Urology. 2009 ; Vol. 73, No. 1. pp. 27-31.
@article{2d25d8e8a4e744dc80539a851a69725d,
title = "A 20-Year Experience With Percutaneous Resection of Upper Tract Transitional Carcinoma: Is There an Oncologic Benefit With Adjuvant Bacillus Calmette Gu{\'e}rin Therapy?",
abstract = "Objectives: To determine whether there is an oncologic benefit of adjuvant bacillus Calmette Gu{\'e}rin (BCG) after resection of upper tract transitional cell carcinoma (UTTCC). Methods: A total of 133 renal units (RU) treated by percutaneous resection for UTTCC between 1985 and 2005 were retrospectively analyzed. Forty-four RU were excluded because of carcinoma in situ, high grade/stage, metastatic disease present at initial presentation, and/or the patient could tolerate loss of RU. Eighty-nine RU treated primarily by percutaneous resection were then analyzed. Fifty RU received adjuvant BCG therapy 2 weeks after endoscopic management for a total of 6 courses. Recurrence was defined as a positive biopsy result after the third-look nephroscopy. Progression of disease was assessed at time of recurrence and defined as an increase in grade/stage of disease. Results: Mean age (± SD) of 89 RU was 70.9 ± 11.1 years. Overall follow-up was 61.1 + 54.8 months. Grade distribution was 56.2{\%} (50 of 89) and 43.8{\%} (39 of 89) for low- and high-grade disease, respectively. There was no statistical difference with regard to tumor grade or stage between treated and nontreated groups (P > .05). Recurrence, time to recurrence, and progression of disease among RU treated with BCG were subselected by grade and compared with the corresponding nontreated group. Statistical significance between any of the treated and nontreated groups was not demonstrated (P > .05). Conclusions: Our data demonstrate that there is no overall oncologic benefit in the administration of adjuvant BCG with regard to disease recurrence, interval to recurrence, and progression of disease in the treatment of UTTCC.",
author = "Rastinehad, {Ardeshir R.} and Ost, {Michael C.} and VanderBrink, {Brian A.} and Greenberg, {Kathryn L.} and Assaad El-Hakim and Robert Marcovich and Badlani, {Gopal H.} and Smith, {Arthur D.}",
year = "2009",
month = "1",
doi = "10.1016/j.urology.2008.06.026",
language = "English (US)",
volume = "73",
pages = "27--31",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A 20-Year Experience With Percutaneous Resection of Upper Tract Transitional Carcinoma

T2 - Is There an Oncologic Benefit With Adjuvant Bacillus Calmette Guérin Therapy?

AU - Rastinehad, Ardeshir R.

AU - Ost, Michael C.

AU - VanderBrink, Brian A.

AU - Greenberg, Kathryn L.

AU - El-Hakim, Assaad

AU - Marcovich, Robert

AU - Badlani, Gopal H.

AU - Smith, Arthur D.

PY - 2009/1

Y1 - 2009/1

N2 - Objectives: To determine whether there is an oncologic benefit of adjuvant bacillus Calmette Guérin (BCG) after resection of upper tract transitional cell carcinoma (UTTCC). Methods: A total of 133 renal units (RU) treated by percutaneous resection for UTTCC between 1985 and 2005 were retrospectively analyzed. Forty-four RU were excluded because of carcinoma in situ, high grade/stage, metastatic disease present at initial presentation, and/or the patient could tolerate loss of RU. Eighty-nine RU treated primarily by percutaneous resection were then analyzed. Fifty RU received adjuvant BCG therapy 2 weeks after endoscopic management for a total of 6 courses. Recurrence was defined as a positive biopsy result after the third-look nephroscopy. Progression of disease was assessed at time of recurrence and defined as an increase in grade/stage of disease. Results: Mean age (± SD) of 89 RU was 70.9 ± 11.1 years. Overall follow-up was 61.1 + 54.8 months. Grade distribution was 56.2% (50 of 89) and 43.8% (39 of 89) for low- and high-grade disease, respectively. There was no statistical difference with regard to tumor grade or stage between treated and nontreated groups (P > .05). Recurrence, time to recurrence, and progression of disease among RU treated with BCG were subselected by grade and compared with the corresponding nontreated group. Statistical significance between any of the treated and nontreated groups was not demonstrated (P > .05). Conclusions: Our data demonstrate that there is no overall oncologic benefit in the administration of adjuvant BCG with regard to disease recurrence, interval to recurrence, and progression of disease in the treatment of UTTCC.

AB - Objectives: To determine whether there is an oncologic benefit of adjuvant bacillus Calmette Guérin (BCG) after resection of upper tract transitional cell carcinoma (UTTCC). Methods: A total of 133 renal units (RU) treated by percutaneous resection for UTTCC between 1985 and 2005 were retrospectively analyzed. Forty-four RU were excluded because of carcinoma in situ, high grade/stage, metastatic disease present at initial presentation, and/or the patient could tolerate loss of RU. Eighty-nine RU treated primarily by percutaneous resection were then analyzed. Fifty RU received adjuvant BCG therapy 2 weeks after endoscopic management for a total of 6 courses. Recurrence was defined as a positive biopsy result after the third-look nephroscopy. Progression of disease was assessed at time of recurrence and defined as an increase in grade/stage of disease. Results: Mean age (± SD) of 89 RU was 70.9 ± 11.1 years. Overall follow-up was 61.1 + 54.8 months. Grade distribution was 56.2% (50 of 89) and 43.8% (39 of 89) for low- and high-grade disease, respectively. There was no statistical difference with regard to tumor grade or stage between treated and nontreated groups (P > .05). Recurrence, time to recurrence, and progression of disease among RU treated with BCG were subselected by grade and compared with the corresponding nontreated group. Statistical significance between any of the treated and nontreated groups was not demonstrated (P > .05). Conclusions: Our data demonstrate that there is no overall oncologic benefit in the administration of adjuvant BCG with regard to disease recurrence, interval to recurrence, and progression of disease in the treatment of UTTCC.

UR - http://www.scopus.com/inward/record.url?scp=57849120619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849120619&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2008.06.026

DO - 10.1016/j.urology.2008.06.026

M3 - Article

C2 - 18929398

AN - SCOPUS:57849120619

VL - 73

SP - 27

EP - 31

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -